FDA Releases Guidance to Promote Nonopioid Alternatives for Chronic Pain
New guidance aims to increase nonopioid choices for chronic pain while combating misuse
One in 10 Undergoing Early Cancer Surgery Have New Persistent Opioid Use
Persons in the highest quartile of morphine milligram equivalents exposure have increased risk for new persistent opioid use
Discontinuation of Medical Cannabis Common in Musculoskeletal Pain
Many patients discontinue medical cannabis within one year, with higher rates for older patients
FDA Approves Sublingual, Nonopioid Daily Treatment for Fibromyalgia
Tonmya is the first FDA-approved therapy for the treatment of fibromyalgia in more than 15 years
Genicular Artery Embolization Safe, Relieves Pain for Symptomatic Knee OA
Significant decrease seen in serum levels of vascular endothelial growth factor and interleukin-1 receptor antagonist at 12 months
AAP Offers Guidance for Tapering of Opioids to Prevent Withdrawal in Children
Signs and symptoms linked with withdrawal are relatively consistent in pediatric population; can be seen after five or more days of opioids
FDA Approves Ketamine Product, KETARx, for Surgical Pain Management
Drugmaker aims to pursue other applications in mental health, neurological, and pain disorders
FDA Approves Ajovy for Migraine Prevention in Children and Teens
Approval is for children and adolescents aged 6 to 17 years weighing ≥45 kg
Cognitive Functional Therapy Effective for Chronic Low Back Pain at Three Years
Cognitive functional therapy, with or without biofeedback, more effective than usual care for chronic disabling low back pain
FDA Requiring Stronger Safety Labels for Opioid Medications
Updated opioid safety labeling is based on new data from two large postmarketing observational studies
